Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Nutritional-GINot yet recruiting Location: QLD Australia

    The effect of withdrawal of oral iron supplementation on airway microbiology and outcomes in cystic fibrosis. , protocol number ACTRN12612000146897

    An open-label study to examine the effects of withdrawal of oral iron supplements on airway iron content and microbiology in patients with CF.

    • Age:

      18 -70 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW AUSTRALIA

    Prevalence of hypoglycaemia and the role of incretins and glucagon during extended oral glucose tolerance test in people with Cystic Fibrosis. , protocol number ACTRN12616001175460

    This study aims to identify the prevalence of hypoglycaemia during extended OGTT's and associations with biochemical parameters relevant to glucose metabolism. In particular, this study will explore the role of glucagon and the incretions GLP-1 and GIP in reactive hypoglycaemia during OGT's.

    • Age:

      18-45 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    Is inhaled tobramycin as effective as intravenous tobramycin and potentially less toxic for treating acute exacerbations of lung infection in those patients with cystic fibrosis (CF) who are chronically colonised with Pseudomonas aeruginosa? , protocol number ACTRN12609000016235

    This study hopes to show that when tobramycin is given via inhalation in those cystic fibrosis patients sick enough to need intravenous (into a vein) antibiotics, the levels in the lung are adequate for effective bacteria elimination and they recover from acute infection. The study will be undertaken in all eligible patients admitted to hospital for treatment of an exacerbation of their lung infection.

    • Age:

      6 Years and older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    An International, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Mixture Formulation Consisting of Liposomal and Free Ciprofloxacin for inhalation Compared with Placebo for inhalation in the Management of Pseudomonas aeruginosa in Patients with Non-Cystic Fibrosis Bronchiectasis with Chronic Lung infections. , protocol number NCT01515007 ACTRN12609000578202

    This study will compare the safety and efficacy of the mixture formulation consisting of liposomal and free ciprofloxacin for inhalation to placebo for inhalation in patients who have confirmed diagnosis of non-CF bronchiectasis with a history of chronic Pseudomonas Aeruginosa infections.

    • Age:

      18 Years to 80 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    A phase 1/11 randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy inhalation in patients with cystic fibrosis(CF). , protocol number ACTRN12610000328077

    The clinical trial is to assess the safety and tolerability and to explore the efficacy of orally inhaled heparin in patients with cystic fibrosis (CF). Heparin is expected to provide advantages over currently available treatments for CF in a convenient delivery system.

    • Age:

      16 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Children and adolescents with cystic fibrosis attending the Women's and Children's Hospital Ambulatory Cystic Fibrosis Physiotherapy Clinic - effect on quality of life, number of occupied bed days, pulmonary function and exercise capacity. , protocol number ACTRN12611000160932

    To determine the effect of participation in the Ambulatory CF Physiotherapy on patients quality of life, lung function, fitness and number of days in hospital.

    • Age:

      0 to 18 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    Randomised trial of the effect of nebulised hypertonic saline in relation to airways clearance physiotherapy, on subjective efficacy, tolerability and overall satisfaction, and lung function parameters in adults with cystic fibrosis lung disease. , protocol number ACTRN12611000673943

    Research question: To determine whether the timing of HS inhalation (before, during or after airway clearance physiotherapy) impacts the subjective efficacy, tolerability and overall satisfaction, of lung function parameters in adults with cystic fibrosis.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis. , protocol number Vertex VX15-661-113

    This two-part study is taking place at multiple care centres across the US. It will look at the safety and tolerability of the drug tezacaftor (VX-661) in combination with ivacaftor. It will also look at how the body processes the drug.

    • Age:

      6-11 years

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      9

    • Length of Participation:

      28 weeks

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    The effect of azithromycin and hypertonic saline on quality of life, lung function and exercise capacity in adults with non-cystic fibrosis bronchiectasis. , protocol number ACTRN12611001199909

    The purpose of this study is to access the efficacy of an oral antibiotic (Azithromycin) and an inhaled mucus-clearance agent (nebulised salt water known as hypertonic saline) in people with bronchiectasis that is not due to cystic fibrosis. The interventions will be administered over a 6 month period. The investigators hypothesise that each intervention will improve the quality of the people with bronchiectasis by reducing the severity of the chronic lung infection.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: NSW - Australia

    Vaccine compared to quadrivalent (ACYW135) meningococcal conjuate vaccine in reducing respiratory exacerbations in children aged greater then or equal to 18 months with suppurative lung disease. , protocol number ACTRN12612000034831

    Chronic suppurative lung diseases in children are major causes of morbidity and mortality worldwide, particularly in disadvantaged populations. Repeated infections in childhood contribute to poor lung health in adulthood. The most common organism associated with infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi (10v-PHiD) can reduce repeated respiratory infections in children. We will be comparing the number of respiratory exacerbation's in the 12 months following vaccinated children with chronic lung disease vaccinated with 10vPHiD and children who received a meningococcal vaccine (control vaccine).

    • Age:

      18 Months to 15 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      0

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Displaying results 51-60 (of 142)
     |<  <  2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11  >  >|